Nicoduce 5mg Tablet (Nicorandil)

Description

Nicoduce 5mg Tablet (Nicorandil) — Complete Clinical and Patient Information Guide

Product Overview

Nicoduce 5mg Tablet (Nicorandil) contains Nicorandil 5mg as its active pharmaceutical ingredient, belonging to the dual-mechanism anti-anginal: organic nitrate + KATP channel opener. It is clinically indicated for stable angina pectoris — particularly when standard anti-anginal agents (beta-blockers, calcium channel blockers, nitrates) alone are insufficient; adjunct anti-anginal in multidrug therapy. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established cardiovascular clinical guidelines.

Nicoduce 5mg provides nicorandil 5mg — a dual-mechanism anti-anginal with a mechanistic profile that differs from all other anti-anginal classes. Its unique KATP channel-opening activity, in addition to nitrate-mediated vasodilation, provides cardioprotective ischaemic preconditioning that extends benefit beyond conventional haemodynamic anti-anginal therapy.

About Nicoduce 5mg and Its Active Ingredient

Nicorandil 5mg is the pharmacologically active compound in Nicoduce 5mg. Cardiovascular medications are among the most safety-critical drugs prescribed — interactions with other heart medications, anticoagulants, and antihypertensives can have life-threatening consequences, and abrupt discontinuation of certain cardiac drugs (beta-blockers, anticoagulants) without medical guidance can precipitate dangerous rebound phenomena. All cardiovascular pharmacotherapy decisions require specialist or physician oversight, with regular monitoring and dose optimisation based on clinical response, ECG findings, blood pressure recordings, and relevant biochemical parameters.

Mechanism of Action

Nicorandil is a unique dual-mechanism anti-anginal agent combining properties of two distinct pharmacological classes in a single molecule: a nitrate group and a nicotinamide group. The nitrate moiety (–ONO2) undergoes organic nitrate metabolism to release nitric oxide (NO) in vascular smooth muscle — NO activates soluble guanylate cyclase, increasing cyclic GMP (cGMP), activating protein kinase G, and causing vasodilation of both coronary arteries (increasing myocardial oxygen supply) and peripheral veins (reducing preload and myocardial oxygen demand). The nicotinamide moiety opens ATP-sensitive potassium channels (KATP channels) in cardiac and vascular smooth muscle membranes — channel opening hyperpolarises the cell membrane, reducing calcium channel activation and producing additional vasodilation. This KATP channel opening also mimics the cardioprotective effects of ischaemic preconditioning, providing direct myocardial protection against ischaemia-reperfusion injury through KATP channel-mediated reduction of calcium overload and mitochondrial protection. The combination of both organic nitrate vasodilation and KATP channel activation produces complete haemodynamic anti-anginal benefit (both preload reduction and coronary vasodilation) while the KATP component provides additional ischaemic preconditioning that extends benefit beyond standard nitrate therapy.

A clear understanding of the pharmacological mechanism helps explain the clinical requirements: why timing, dose titration, monitoring, drug interactions, and contraindications exist. Healthcare providers use mechanistic knowledge to individualise therapy, anticipate interactions, and monitor for treatment response and toxicity.

Clinical Indications

Nicoduce 5mg Tablet (Nicorandil) is clinically indicated for:

• Primary indication: stable angina pectoris — particularly when standard anti-anginal agents (beta-blockers, calcium channel blockers, nitrates) alone are insufficient; adjunct anti-anginal in multidrug therapy
• Specialist assessment required: Cardiovascular drug therapy must be initiated and monitored by a qualified cardiologist, physician, or specialist. Self-diagnosis and self-treatment of cardiac conditions is dangerous and may delay life-saving treatment.

Dosage and Administration

Start 5mg twice daily (or OD for modified-release formulations), increasing to 10–20mg twice daily as needed. Take with or without food. IMPORTANT: Inform your doctor and pharmacist about all other medications — PDE5 inhibitors (sildenafil, tadalafil) are absolutely contraindicated.

Never adjust the dose or stop cardiovascular medications without consulting your prescribing physician. Abrupt withdrawal of beta-blockers, anticoagulants, and anti-anginal drugs can cause dangerous rebound phenomena including angina exacerbation, myocardial infarction, and thromboembolic events.

Who Should Use Nicoduce 5mg

Nicoduce 5mg is indicated for adult patients in whom the relevant cardiovascular condition has been confirmed by clinical assessment and appropriate investigations (ECG, echocardiogram, cardiac biomarkers, blood pressure recording, coagulation studies as applicable) and in whom this specific pharmacological approach has been determined to be clinically appropriate after benefit-risk assessment.

Contraindications

Cardiogenic shock. Severe hypotension. Left ventricular failure with low filling pressures. PDE5 inhibitors (concurrent use potentiates hypotension — avoid sildenafil, tadalafil, vardenafil). Hypovolaemia. Hypersensitivity to nicorandil.

Drug Interactions

PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil): ABSOLUTE CONTRAINDICATION — combined with nicorandil’s nitrate component causes profound, potentially life-threatening hypotension through additive cGMP elevation (same mechanism as nitrate + PDE5 inhibitor interaction). Antihypertensives and other vasodilators: additive hypotension. Tricyclic antidepressants: enhanced hypotensive effect.

Cardiovascular drugs have numerous clinically significant, potentially dangerous drug interactions. A comprehensive medication review by a cardiologist or clinical pharmacist is essential before initiating or changing any cardiac medication. Patients must inform all healthcare providers (including dentists, surgeons, and emergency physicians) of all their cardiovascular medications.

Adverse Effects

Common: Headache (from nitrate component — typically diminishes with continued use), flushing, and dizziness. Important — Nicorandil mucosal ulceration: Nicorandil is uniquely associated with mucosal ulceration — oral ulcers (most common), anal and perineal ulcers, cutaneous fistulae, and gastrointestinal ulceration. These can be severe and debilitating. Patients must be informed of this risk and advised to report any persistent oral, perineal, or GI ulcers immediately. Nicorandil should be stopped if mucosal ulceration is confirmed. Uncommon: Hypotension, tachycardia, nausea.

Special Population Considerations

IMPORTANT — Nicorandil mucosal ulceration: This is a unique and important adverse effect of nicorandil not seen with other anti-anginal drugs. Oral ulcers (aphthous-type), perianal ulcers, skin fistulae, and GI ulceration have been reported — sometimes severe and debilitating. Patients must immediately report any new or persistent oral ulcers, perianal discomfort, or unusual skin wounds to their prescriber. If confirmed as nicorandil-related, the drug must be stopped — ulcers typically resolve on discontinuation. KATP channel ischaemic preconditioning: Nicorandil’s KATP channel-opening activity mimics ischaemic preconditioning — a potential direct myoprotective benefit beyond anti-anginal haemodynamic effects that distinguishes it from pure nitrates.

Storage and Handling

Store Nicoduce 5mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use beyond the printed expiry date. Nitroglycerin preparations require special storage in airtight glass containers away from heat — plastic and light degrade GTN. Enoxaparin: store at room temperature; do not freeze.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose. Never double-dose. Do not stop beta-blockers, anticoagulants, or anti-anginal medications abruptly without medical advice.

Q: Why is nicorandil sometimes preferred over conventional nitrates?
A: Nicorandil’s dual KATP channel + nitrate mechanism provides more complete anti-anginal benefit than nitrates alone — addressing both preload reduction (nitrate component) and providing direct myocardial protection through KATP channel ischaemic preconditioning (KATP component). Additionally, nicorandil is less prone to nitrate tolerance than conventional organic nitrates, as the KATP channel component maintains efficacy even when the nitrate component develops tolerance with continuous use.

Evidence Base and Cardiovascular Guidelines

The active ingredient in Nicoduce 5mg has been evaluated in landmark randomised controlled trials and is supported by major international cardiovascular guidelines including those from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Heart Association, National Institute for Health and Care Excellence (NICE), and relevant national cardiovascular specialist bodies. These guidelines represent evidence-based consensus on optimal pharmacological management of cardiovascular conditions and are regularly updated as new clinical evidence emerges.

Cardiovascular disease management has undergone transformative advances over the past three decades — from the landmark MERIT-HF, CAPRICORN, and EMPHASIS-HF trials establishing guideline-directed medical therapy for heart failure, to the COURAGE trial for stable angina, EINSTEIN for anticoagulation, and ADVANCE-HF for newer agents. Patients benefit most when their individual pharmacotherapy aligns with current evidence-based guidelines.

Patient Counselling Points

• Never stop abruptly: Beta-blockers, anti-anginal drugs, and anticoagulants must never be stopped suddenly without medical guidance — abrupt withdrawal can trigger angina rebound, myocardial infarction, arrhythmia, or thromboembolic events.
• Carry a medication list: All patients on cardiovascular drugs should carry a current medication list for any medical encounter — including surgical, dental, and emergency care. Drug interactions in cardiovascular patients can be life-threatening.
• Regular monitoring: Blood pressure, ECG, renal function, electrolytes (for diuretics), INR (for warfarin), platelet count (for heparins), and cardiac biomarkers as appropriate should be monitored at intervals determined by your cardiologist.
• Lifestyle integration: Pharmacotherapy delivers best results alongside appropriate lifestyle modification: Mediterranean diet, regular aerobic exercise, smoking cessation, moderate alcohol, sodium restriction for hypertension and heart failure.

Cardiovascular Disease Context and Clinical Management Principles

Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 18 million deaths annually — representing 32% of all global mortality. Coronary artery disease, heart failure, hypertension, stroke, and peripheral arterial disease collectively impose an enormous burden of mortality, morbidity, and reduced quality of life worldwide. The last five decades have witnessed transformative advances in cardiovascular pharmacotherapy — from the introduction of beta-blockers and ACE inhibitors, through the development of statins and thrombolytics, to the current era of guideline-directed medical therapy with proven mortality-reducing agents for heart failure, and novel anticoagulants revolutionising stroke prevention in atrial fibrillation.

Effective cardiovascular disease management requires integration of pharmacological therapy with lifestyle modification (Mediterranean diet, regular aerobic exercise, smoking cessation, alcohol moderation, sodium restriction), risk factor control (blood pressure, lipid management, glycaemic control, weight management), and appropriate interventional or surgical procedures where indicated. Pharmacotherapy alone, without lifestyle integration and risk factor management, provides suboptimal benefit — drugs and lifestyle modification are synergistic, not alternative, approaches.

Hypertension: The Silent Cardiovascular Risk Factor

Hypertension affects approximately 1.28 billion adults worldwide, yet only 21% of hypertensive adults have their blood pressure adequately controlled. Uncontrolled hypertension is the leading modifiable risk factor for stroke, coronary artery disease, heart failure, renal failure, and peripheral arterial disease. The relationship between blood pressure and cardiovascular risk is continuous — even high-normal blood pressure (130–139/85–89 mmHg) carries increased cardiovascular risk compared to optimal levels.

Current international guidelines (ESC/ESH, ACC/AHA, NICE) recommend initial drug therapy for hypertension with one of three evidence-based drug classes: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); calcium channel blockers (CCBs); or thiazide/thiazide-like diuretics. Most patients with stage 2 hypertension (≥160/100 mmHg) require combination therapy from initial diagnosis. Fixed-dose combination tablets — such as those in this product range — improve adherence and simplify therapy for patients requiring multiple agents.

Angina Pectoris: Management Principles

Stable angina pectoris affects over 110 million people globally and represents myocardial ischaemia occurring predictably with exertion or emotional stress, relieved by rest or sublingual nitroglycerin within minutes. The management goal is threefold: symptom relief, prevention of disease progression and MI, and improvement of quality of life. First-line symptomatic therapy uses beta-blockers and/or calcium channel blockers as rate-limiting or vasodilatory agents; long-acting nitrates or nicorandil are added when first-line therapy is insufficient. For resistant symptoms, trimetazidine or ivabradine (when HR remains elevated) provide additional anti-anginal mechanisms. When pharmacological therapy fails to control symptoms adequately, coronary revascularisation (PCI or CABG) should be considered.

Quality Standards and Evidence Base

The active ingredients in products in this range have been evaluated in landmark randomised controlled trials that form the foundation of evidence-based cardiovascular medicine: MERIT-HF (metoprolol succinate in HFrEF), CAPRICORN and COPERNICUS (carvedilol in post-MI LV dysfunction and HFrEF), BEAUTIFUL (ivabradine in stable CAD), SIGNIFY (ivabradine in stable angina), EINSTEIN (enoxaparin in VTE), EXTRACT-TIMI 25 (enoxaparin in STEMI), and IONA (nicorandil in stable angina). Major cardiovascular guidelines from the ESC, ACC/AHA, and NICE incorporate these drugs into evidence-based treatment algorithms based on the totality of this evidence.

Products are manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities, ensuring consistent quality, identity, strength, and purity. Patients should always obtain prescription cardiovascular medications from licensed pharmacies with valid prescriptions to ensure receipt of authentic, properly stored, quality-assured products.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed cardiology literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified cardiologist, physician, or pharmacist. Cardiovascular drug therapy decisions must be individualised by a licensed healthcare provider with full knowledge of the patient’s cardiac status, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of cardiovascular conditions can be dangerous and life-threatening. Always consult a qualified cardiologist or physician before starting, changing, or stopping any cardiovascular medication.